<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35053327</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11020209</ELocationID><Abstract><AbstractText>Diagnosis of ALS is based on clinical symptoms when motoneuron degeneration is significant. Therefore, new approaches for early diagnosis are needed. We aimed to assess if alterations in appearance and cellular localization of cutaneous TDP-43 may represent a biomarker for ALS. Skin biopsies from 64 subjects were analyzed: 44 ALS patients, 10 healthy controls (HC) and 10 neurological controls (NC) (Parkinson's disease and multiple sclerosis). TDP-43 immunoreactivity in epidermis and dermis was analyzed, as well as the percentage of cells with TDP-43 cytoplasmic localization. We detected a higher amount of TDP-43 in epidermis (<i>p</i> &lt; 0.001) and in both layers of dermis (<i>p</i> &lt; 0.001), as well as a higher percentage of TDP-43 cytoplasmic positive cells (<i>p</i> &lt; 0.001) in the ALS group compared to HC and NC groups. Dermal cells containing TDP-43 were fibroblasts as identified by co-labeling against vimentin. ROC analyses (AUC 0.867, <i>p</i> &lt; 0.001; CI 95% 0.800-0.935) showed that detection of 24.1% cells with cytoplasmic TDP-43 positivity in the dermis had 85% sensitivity and 80% specificity for detecting ALS. We have identified significantly increased TDP-43 levels in epidermis and in the cytoplasm of dermal cells of ALS patients. Our findings provide support for the use of TDP-43 in skin biopsies as a potential biomarker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0735-6854</Identifier><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrando-Grabulosa</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Roser</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3194-9406</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuro-Oncology Unit, Department of Neurology, Hospital Universitari de Bellvitge-ICO and IDIBELL, 08907 L'Hospitalet, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>Israel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-8806-8733</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitari de Bellvitge, 08907 L'Hospitalet, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-9849-902X</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RTI2018-096386-B-I00</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004817" MajorTopicYN="N">Epidermis</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">dermis</Keyword><Keyword MajorTopicYN="N">skin biopsy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35053327</ArticleId><ArticleId IdType="pmc">PMC8773870</ArticleId><ArticleId IdType="doi">10.3390/cells11020209</ArticleId><ArticleId IdType="pii">cells11020209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Van Den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:1&#x2013;19. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog. Neurobiol. 2015;133:1&#x2013;26. doi: 10.1016/j.pneurobio.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.07.004</ArticleId><ArticleId IdType="pubmed">26253783</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Wray N.R., Henderson R.D. Extra-motor abnormalities in amyotrophic lateral sclerosis: Another layer of heterogeneity. Expert Rev. Neurother. 2017;17:561&#x2013;577. doi: 10.1080/14737175.2017.1273772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2017.1273772</ArticleId><ArticleId IdType="pubmed">27983884</ArticleId></ArticleIdList></Reference><Reference><Citation>McCluskey L., Vandriel S., Elman L., Van Deerlin V.M., Powers J., Boller A., Wood E.M., Woo J., McMillan C.T., Rascovsky K., et al. ALS-Plus syndrome: Non-pyramidal features in a large ALS cohort. J. Neurol. Sci. 2014;345:118&#x2013;124. doi: 10.1016/j.jns.2014.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.07.022</ArticleId><ArticleId IdType="pmc">PMC4177937</ArticleId><ArticleId IdType="pubmed">25086858</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2008;9:323&#x2013;338. doi: 10.1080/17482960802372371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802372371</ArticleId><ArticleId IdType="pubmed">18752088</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J., Pender N., Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong L.K., Neumann M., Sampathu D.M., Lee V.M.-Y., Trojanowski J.Q. TDP-43 proteinopathy: The neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114:63&#x2013;70. doi: 10.1007/s00401-007-0226-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0226-5</ArticleId><ArticleId IdType="pubmed">17492294</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Suh E.R., Van Deerlin V.M., Wood E.M., Baek Y., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. Molecular Neuropathology of TDP-43 Proteinopathies. Int. J. Mol. Sci. 2009;10:232&#x2013;246. doi: 10.3390/ijms10010232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms10010232</ArticleId><ArticleId IdType="pmc">PMC2662455</ArticleId><ArticleId IdType="pubmed">19333444</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Ludolph A.C., Neumann M., Ravits J., Del Tredici K. Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal &#x3b1;-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:79&#x2013;90. doi: 10.1007/s00401-016-1633-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1633-2</ArticleId><ArticleId IdType="pmc">PMC5209403</ArticleId><ArticleId IdType="pubmed">27757524</ArticleId></ArticleIdList></Reference><Reference><Citation>Clos A.L., Kayed R., Lasagna-Reeves C.A. Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis. Front. Neurol. 2012;3:5. doi: 10.3389/fneur.2012.00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2012.00005</ArticleId><ArticleId IdType="pmc">PMC3262151</ArticleId><ArticleId IdType="pubmed">22319507</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Mikami H., Watanabe T., Yamano T., Yamazaki T., Nomura M., Yasui K., Ishikawa H., Ono S. Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. Acta Neurol. Scand. 2010;122:367&#x2013;372. doi: 10.1111/j.1600-0404.2010.01321.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2010.01321.x</ArticleId><ArticleId IdType="pubmed">20175762</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhou S., Ding X., Ma M., Zhang J., Zhou Y., Wu E., Teng J. Activation of ER Stress and Autophagy Induced by TDP-43 A315T as Pathogenic Mechanism and the Corresponding Histological Changes in Skin as Potential Biomarker for ALS with the Mutation. Int. J. Biol. Sci. 2015;11:1140&#x2013;1149. doi: 10.7150/ijbs.12657.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.12657</ArticleId><ArticleId IdType="pmc">PMC4551750</ArticleId><ArticleId IdType="pubmed">26327808</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; B., Touzel-Desch&#xea;nes L., Lamontagne R., Lamarre M.-S., Scott F.-D., Khuong H.T., Dion P.A., Bouchard J.-P., Gould P., Rouleau G.A., et al. Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients. Acta Neuropathol. Commun. 2015;3:1&#x2013;12. doi: 10.1186/s40478-014-0181-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0181-z</ArticleId><ArticleId IdType="pmc">PMC4359444</ArticleId><ArticleId IdType="pubmed">25637145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M., Zollino M., Conte A., Del Grande A., Marangi G., Lucchini M., Mirabella M., Romano A., Piacentini R., Bisogni G., et al. Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. Neurobiol. Aging. 2015;36:2005-e5&#x2013;2005-e13. doi: 10.1016/j.neurobiolaging.2015.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.02.009</ArticleId><ArticleId IdType="pubmed">25792239</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Zhang K.Y., Kariawasam R., Bax M., Fifita J.A., Ooi L., Yerbury J.J., Nicholson G.A., Blair I.P. Evaluation of Skin Fibroblasts from Amyotrophic Lateral Sclerosis Patients for the Rapid Study of Pathological Features. Neurotox. Res. 2015;28:138&#x2013;146. doi: 10.1007/s12640-015-9532-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-015-9532-1</ArticleId><ArticleId IdType="pubmed">26013250</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Ohkubo T., Yokota T. TDP-43 in the skin of amyotrophic lateral sclerosis patients. J. Med. Dent. Sci. 2017;64:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28367944</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J., Castanedo-V&#xe1;zquez D., Gil-Bea F., Tapia O., Arozamena J., Dur&#xe1;n-V&#xed;an C., Sedano M.J., Berciano M.T., De Munain A.L., Lafarga M. ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage. J. Neurol. 2020;267:1291&#x2013;1299. doi: 10.1007/s00415-020-09704-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09704-8</ArticleId><ArticleId IdType="pubmed">31938860</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano N., Catalani A., Lattante S., Belardo A., Proietti S., Bertini L., Ceci M. ALS skin fibroblasts reveal oxidative stress and ERK1/2-mediated cytoplasmic localization of TDP-43. Cell. Signal. 2020;70:109591. doi: 10.1016/j.cellsig.2020.109591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2020.109591</ArticleId><ArticleId IdType="pubmed">32126264</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., Zwahlen M., Kampf C., Wester K., Hober S., et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 2010;28:1248&#x2013;1250. doi: 10.1038/nbt1210-1248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1210-1248</ArticleId><ArticleId IdType="pubmed">21139605</ArticleId></ArticleIdList></Reference><Reference><Citation>Thul P.J., &#xc5;kesson L., Wiking M., Mahdessian D., Geladaki A., Blal H.A., Alm T., Asplund A., Bj&#xf6;rk L., Breckels L.M., et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321. doi: 10.1126/science.aal3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3321</ArticleId><ArticleId IdType="pubmed">28495876</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron. Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams S.M., Khan G., Harris B.T., Ravits J., Sierks M.R. TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis. BMC Neurosci. 2017;18:1&#x2013;12. doi: 10.1186/s12868-017-0334-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-017-0334-7</ArticleId><ArticleId IdType="pmc">PMC5264476</ArticleId><ArticleId IdType="pubmed">28122516</ArticleId></ArticleIdList></Reference><Reference><Citation>Codron P., Cassereau J., Vourc&#x2019;H P., Veyrat-Durebex C., Blasco H., Kane S., Procaccio V., Letournel F., Verny C., Lenaers G., et al. Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions. Amyotroph. Lateral Scler. Front. Degener. 2018;19:446&#x2013;456. doi: 10.1080/21678421.2018.1431787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431787</ArticleId><ArticleId IdType="pubmed">29382228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y., Liu W., Li Y., Sun B., Li Y., Yang F., Wang H., Li M., Cui F., Huang X. Cutaneous somatic and autonomic nerve TDP-43 deposition in amyotrophic lateral sclerosis. J. Neurol. 2018;265:1753&#x2013;1763. doi: 10.1007/s00415-018-8897-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8897-5</ArticleId><ArticleId IdType="pubmed">29804146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S. The skin in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:191&#x2013;199. doi: 10.1080/14660820050515188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515188</ArticleId><ArticleId IdType="pubmed">11464952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Tan C.-F., Mori F., Tanji K., Kakita A., Takahashi H., Wakabayashi K. TDP-43-immunoreactive neuronal and glial inclusions in the neostriatum in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2007;115:115&#x2013;122. doi: 10.1007/s00401-007-0285-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0285-7</ArticleId><ArticleId IdType="pubmed">17786458</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; B., Gros-Louis F. Potential skin involvement in ALS: Revisiting Charcot&#x2019;s observation&#x2013;a review of skin abnormalities in ALS. Rev. Neurosci. 2017;28:551&#x2013;572. doi: 10.1515/revneuro-2017-0004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2017-0004</ArticleId><ArticleId IdType="pubmed">28343168</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L.K., Lee E.B., Kremmer E., Flatley A., Xu Y., Lee V.M.Y. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y., Mori F., Nunomura J., Ookawa K., Yajima N., Yagihashi S., Wakabayashi K. Sporadic amyotrophic lateral sclerosis with pallido-nigro-luysian degeneration: A TDP-43 immunohistochemical study. Neuropathology. 2010;30:149&#x2013;153. doi: 10.1111/j.1440-1789.2009.01046.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01046.x</ArticleId><ArticleId IdType="pubmed">19703266</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Xu Y., Truax A.C., Uryu K., Neumann M., Clark C.M., Elman L.B., Miller B.L., Grossman M., et al. Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Am. J. Pathol. 2008;173:182&#x2013;194. doi: 10.2353/ajpath.2008.080003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080003</ArticleId><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y., Tan C.-F., Onodera O., Toyoshima Y., Yamada M., Morita T., Nishizawa M., Kakita A., Takahashi H. Sporadic amyotrophic lateral sclerosis: Two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol. 2008;116:169&#x2013;182. doi: 10.1007/s00401-008-0385-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0385-z</ArticleId><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K., Tank E.M., Miguez R., McBride J.P., G&#xf3;mez N.B., White M., Lin Z., Gonzalez C.M., Serio A., Sreedharan J., et al. Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J. Clin. Investig. 2020;130:1139&#x2013;1155. doi: 10.1172/JCI130988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130988</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis J., Katona I., Muller-Newen G., Sommer C., Necula G., Hendrich C., Ludolph A.C., Sperfeld A.-D. Small-fiber neuropathy in patients with ALS. Neurology. 2011;76:2024&#x2013;2029. doi: 10.1212/WNL.0b013e31821e553a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821e553a</ArticleId><ArticleId IdType="pubmed">21646630</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Dengler R., Eisen A., England J.D., Kaji R., Kimura J., Swash M. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Al-Chalabi A., Baker M.R., Cui L.-Y., de Carvalho M., Eisen A., Grosskreutz J., Hardiman O., Henderson R., Matamala J.M., et al. A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 2020;131:1975&#x2013;1978. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese F., Sartori A., Logroscino G., Pisa F.E. Predictors of diagnostic delay in amyotrophic lateral sclerosis: A cohort study based on administrative and electronic medical records data. Amyotroph. Lateral Scler. Front. Degener. 2019;20:176&#x2013;185. doi: 10.1080/21678421.2018.1550517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550517</ArticleId><ArticleId IdType="pubmed">30656971</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E., Lee A., Murphy A., Chang J., Zipf A., Cudkowicz M., Atassi N. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph. Lateral Scler. Front. Degener. 2014;15:453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E., Gray E., Ansorge O., Talbot K., Turner M. Towards a TDP-43-Based Biomarker for ALS and FTLD. Mol. Neurobiol. 2018;55:7789&#x2013;7801. doi: 10.1007/s12035-018-0947-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E., Kuiperij H.B., Van Blitterswijk M.M., Veldink J.H., Schelhaas H.J., Van Den Berg L.H., Verbeek M.M. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012;13:446&#x2013;451. doi: 10.3109/17482968.2012.703208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.703208</ArticleId><ArticleId IdType="pubmed">22873561</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G., Lomartire A., Calvo A., Risso A., De Luca E., Mostert M., Chi&#xf2; A. Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP-43 subcellular distribution. Neuropathol. Appl. Neurobiol. 2017;43:133&#x2013;153. doi: 10.1111/nan.12328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12328</ArticleId><ArticleId IdType="pubmed">27178390</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G., Lupino E., Calvo A., Moglia C., Buccinna B., Grifoni S., Chio A. Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol. 2011;121:611&#x2013;622. doi: 10.1007/s00401-010-0786-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0786-7</ArticleId><ArticleId IdType="pubmed">21120508</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila A., Kuvaja M., Hartikainen P., Siloaho M., Helisalmi S., Moilanen V., Kiviharju A., Jansson L., Tienari P.J., Remes A.M., et al. Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. Dement. Geriatr. Cogn. Disord. Extra. 2016;6:142&#x2013;149. doi: 10.1159/000444788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000444788</ArticleId><ArticleId IdType="pmc">PMC4868946</ArticleId><ArticleId IdType="pubmed">27195002</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto Y.-I., Shibuya K., Sato Y., Kanai K., Misawa S., Sawai S., Mori M., Uchiyama T., Isose S., Nasu S., et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value. Amyotroph. Lateral Scler. 2010;12:140&#x2013;143. doi: 10.3109/17482968.2010.541263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.541263</ArticleId><ArticleId IdType="pubmed">21126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T., Tokuda T., Ishigami N., Sasayama H., Foulds P., Mitchell D.J., Mann D.M.A., Allsop D., Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55&#x2013;62. doi: 10.1007/s00401-008-0456-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0456-1</ArticleId><ArticleId IdType="pubmed">18989684</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Hendrich C., Sperfeld A.D., Jesse S., von Arnim C.A.F., Lehnert S., Pabst A., Uttner I., Tumani H., Lee V.M.-Y., et al. TDP-43 in Cerebrospinal Fluid of Patients with Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Arch. Neurol. 2008;65:1481&#x2013;1487. doi: 10.1001/archneur.65.11.1481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1481</ArticleId><ArticleId IdType="pmc">PMC2690860</ArticleId><ArticleId IdType="pubmed">19001167</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., Lautner R., Andreasson U., &#xd6;hrfelt A., Portelius E., Bjerke M., H&#xf6;ltt&#xe4; M., Ros&#xe9;n C., Olsson C., Strobel G., et al. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;684. doi: 10.1016/S1474-4422(16)00070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>